Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Issuance of U.S. Patent No. 11,351,225 Further Enhances Ocugen's Gene Therapy Intellectual Property Portfolio Issuance of U.S. Patent No. 11,351,225 Further Enhances Ocugen's Gene Therapy Intellectual Property Portfolio

Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy

Shareholders could be hit with a high degree of stock dilution soon.

Why Ocugen Stock Flopped on Friday

MALVERN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that Michael Shine, Ocugen's Senior Vice President, Commercial, will present at the 2022 BIO International Convention being held in San Diego, California, from June 13-16, 2022.

Ocugen, Inc. to Present at BIO International Convention 2022

Peloton

2 Struggling Stocks That Aren't Likely to Recover Anytime Soon

Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).

Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA

Ocugen Inc (NASDAQ: OCGN) says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart (autologous chondrocyte-derived neocartilage).  Recently, the FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to.

Ocugen Diversifies Its Pipeline With New Cell Therapy Platform

NeoCart® (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative medicines

Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Shares of the biotech company are falling despite news that the FDA has cleared it to resume clinical trials of its Covid-19 vaccine. The post OCGN Stock Falls Despite Positive FDA Update appeared first on InvestorPlace.

OCGN Stock Falls Despite Positive FDA Update

The FDA has lifted the clinical hold on Ocugen Inc's (NASDAQ: OCGN) Phase 2/3 trial, OCU-002, for Covaxin (BBV152), a whole virus inactivated COVID-19 vaccine candidate.  In April, the agency paused the trials of the shot, Covaxin, after an inspection of a Bharat Biotech.

FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial

MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will participate in an in-person fireside chat at the H.C. Wainwright Global Investment Conference, on May 24, 2022, at 1:30pm ET in Miami Beach, Florida.

Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference

Ocugen Inc. shares OCGN, -0.45% jumped 9% premarket Monday, after the biotech said the Food and Drug Administration has lifted its clinical hold on Ocugen's Phase 2/3 trial of its COVID-19 vaccine candidate Covaxin. "We're extremely pleased that we can proceed with our clinical trials for COVAXIN(TM), our whole virus inactivated COVID-19 vaccine candidate.

Ocugen shares jump premarket after FDA lifts clinical hold on trial of COVID-19 vaccine candidate

Dosing to Resume Immediately Dosing to Resume Immediately

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)

It's entering a new market -- one that has authorized its vaccine.

Is Ocugen Finally on the Way to Vaccine Revenue?

Can the company return to its 2021 highs?

Where Will Ocugen Be in 1 Year?

Ocugen, Inc. (NASDAQ:OCGN ) Q1 2022 Earnings Conference Call May 6, 2022 8:30 AM ET Company Participants Ken Inchausti - Head, Investor Relations & Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Jessica Crespo - Chief Accounting Officer & Senior Vice President, Finance Conference Call Participants Zegbeh Jallah - ROTH Capital Partners Swayampakula Ramakanth - H.C. Wainwright Operator Good morning, and welcome to the Ocugen Conference Call.

Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q1 2022 Results - Earnings Call Transcript

Ocugen (OCGN) delivered earnings and revenue surprises of -280% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ocugen (OCGN) Reports Q1 Loss, Misses Revenue Estimates

Conference Call and Webcast Today at 8:30 a.m. ET

Ocugen Provides Business Update and First Quarter 2022 Financial Results

MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced that it will host a conference call to provide a business update and discuss its first quarter 2022 financial results at 8:30 a.m. ET on Friday, May 6, 2022.

Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results

BioXcel Therapeutics

Sometimes analysts are on the spot, and other times, not so much.

2 Small-Cap Stocks With Monster Upsides, According to Wall Street

MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced two presentations on the company's research into the development of a modifier gene therapy to treat dry age-related macular degeneration (AMD), and a novel biologic to treat wet-AMD and diabetic macular edema (DME) at The Association for Research in Vision and Ophthalmology's (ARVO) 2022 Annual Meeting in Denver on May 1 - 4, 2022.

Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

Could the hype surrounding this once-popular meme stock return?

Is It Too Late to Buy Ocugen Stock?

WIth Ocugen, there's nothing to get excited about here. Avoid the OCGN stock, as it heads significantly lower.

The Top Reasons to Avoid the Ocugen Stock

Regulators are displeased, and might inflict a penalty on the biopharmaceutical company.

The FDA Just Sent Ocugen a Warning. Should Investors Care?

Bionano Genomics

Intercept Pharma

Select analysts see these small-cap stocks skyrocketing over the next 12 months.

3 Moonshot Stocks With Upside of Up to 709%, According to Wall Street

Phase 1/2 study to assess the safety and efficacy of OCU400 modifier gene therapy candidate to treat Retinitis Pigmentosa associated with NR2E3 and RHO mutations Phase 1/2 study to assess the safety and efficacy of OCU400 modifier gene therapy candidate to treat Retinitis Pigmentosa associated with NR2E3 and RHO mutations

News for Ocugen, Inc. Stock (OCGN)